Psoriasis Market Outlook: Targeted Innovation Amidst Growing Competitive Pressure
The psoriasis treatment landscape is evolving rapidly, with interleukin inhibitors—particularly IL-17 and IL-23 agents—driving market growth. Despite biosimilar erosion of legacy anti-TNF therapies like Humira and Stelara, the market is forecast to grow to $18.8bn by 2031 across the US, EU5, and Japan, fueled by rising prevalence, new oral therapies, and pipeline innovation.
Skyrizi has emerged as a market leader, with blockbuster sales expected to exceed $7bn annually by the end of the forecast period. Meanwhile, Sotyktu, a novel oral TYK2 inhibitor, is poised to challenge Otezla and expand the market by offering a more efficacious oral option.
In this report we cover:
- Key growth drivers: Uptake of IL-17 and IL-23 inhibitors, biosimilar launches, and increasing prevalence across major markets.
- Promising therapies: Skyrizi, Tremfya, Bimzelx, Sotyktu, and biosimilars to Humira and Stelara.
- Novel modalities: TYK2 inhibitors, IL-36 receptor blockers for GPP, and next-gen topicals like Zoryve and Vtama.
